全文获取类型
收费全文 | 25945篇 |
免费 | 1385篇 |
国内免费 | 289篇 |
专业分类
耳鼻咽喉 | 103篇 |
儿科学 | 1088篇 |
妇产科学 | 173篇 |
基础医学 | 1723篇 |
口腔科学 | 21篇 |
临床医学 | 3690篇 |
内科学 | 6014篇 |
皮肤病学 | 98篇 |
神经病学 | 234篇 |
特种医学 | 2226篇 |
外国民族医学 | 2篇 |
外科学 | 2331篇 |
综合类 | 4656篇 |
预防医学 | 1668篇 |
眼科学 | 20篇 |
药学 | 2080篇 |
23篇 | |
中国医学 | 631篇 |
肿瘤学 | 838篇 |
出版年
2024年 | 22篇 |
2023年 | 320篇 |
2022年 | 790篇 |
2021年 | 968篇 |
2020年 | 894篇 |
2019年 | 696篇 |
2018年 | 724篇 |
2017年 | 721篇 |
2016年 | 828篇 |
2015年 | 868篇 |
2014年 | 1917篇 |
2013年 | 1700篇 |
2012年 | 1687篇 |
2011年 | 1737篇 |
2010年 | 1411篇 |
2009年 | 1351篇 |
2008年 | 1398篇 |
2007年 | 1459篇 |
2006年 | 1272篇 |
2005年 | 1067篇 |
2004年 | 816篇 |
2003年 | 648篇 |
2002年 | 469篇 |
2001年 | 503篇 |
2000年 | 397篇 |
1999年 | 381篇 |
1998年 | 303篇 |
1997年 | 268篇 |
1996年 | 190篇 |
1995年 | 252篇 |
1994年 | 208篇 |
1993年 | 153篇 |
1992年 | 139篇 |
1991年 | 116篇 |
1990年 | 121篇 |
1989年 | 100篇 |
1988年 | 96篇 |
1987年 | 87篇 |
1986年 | 59篇 |
1985年 | 82篇 |
1984年 | 68篇 |
1983年 | 22篇 |
1982年 | 65篇 |
1981年 | 45篇 |
1980年 | 36篇 |
1979年 | 42篇 |
1978年 | 31篇 |
1977年 | 33篇 |
1976年 | 20篇 |
1974年 | 11篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
《Revista portuguesa de cardiologia》2022,41(9):783-789
Amiodarone is the most potent antiarrhythmic drug available and is commonly prescribed to treat and prevent not only life-threatening ventricular arrhythmias but also atrial fibrillation (AF). The latest European Society of Cardiology AF guidelines state that amiodarone is recommended for long-term rhythm control in all AF patients but that other antiarrhythmic drugs should be considered first whenever possible, due to its extracardiac toxicity. In patients without significant or with only minimal structural heart disease, amiodarone is not listed as a possibility in their therapeutic scheme. Still, amiodarone is widely and liberally used, and is the most prescribed antiarrhythmic drug for patients with AF despite its high toxicity profile. Non-cardiovascular death was more frequent with amiodarone treatment than with a rate control strategy in AFFIRM, while meta-analyses suggest an association between amiodarone use in patients without structural heart disease and increased non-cardiovascular mortality. Severe or even fatal outcomes due to amiodarone may occur years after treatment initiation and are often not acknowledged by the prescribing physician, who may no longer be following the patient. The lack of widely accepted diagnostic criteria and symptom definitions may lead to underestimation of the incidence of severe side effects and of its toxicity. Unlike the underestimated risk of toxicity with amiodarone, severe complications associated with catheter ablation are usually directly ascribed to the treatment even by non-medical personnel, possibly resulting in overestimation of risks. This brief review will address the issue of amiodarone overuse and the frequent underestimation of its toxicity, while suggesting scenarios in which its use is entirely reasonable, and compare it with catheter ablation. 相似文献
2.
3.
4.
5.
6.
9.
《Journal of the American College of Radiology》2022,19(3):407-414
ObjectiveTo evaluate the impact of structured recommendations on follow-up completion for incidental lung nodules (ILNs).MethodsPatients with ILNs before and after implementation of structured Fleischner recommendations and electronic tracking were sampled randomly. The cohorts were compared for imaging follow-up. Multivariable logistic regression was used to assess appropriate follow-up and loss to follow-up, with independent variables including use of structured recommendations or tracking, age, sex, race, ethnicity, setting of the index test (inpatient, outpatient, emergency department), smoking history, and nodule features.ResultsIn all, 1,301 patients met final inclusion criteria, including 255 patients before and 1,046 patients after structured recommendations or tracking. Baseline differences were found in the pre- and postintervention groups, with smaller ILNs and younger age after implementing structured recommendations. Comparing pre- versus postintervention outcomes, 40.0% (100 of 250) versus 29.5% (309 of 1,046) of patients had no follow-up despite Fleischner indications for imaging (P = .002), and among the remaining patients, 56.6% (82 of 145) versus 75.0% (553 of 737) followed up on time (P < .001). Delayed follow-up was more frequent before intervention. Differences postintervention were mostly accounted for by nodules ≤8 mm in the outpatient setting (P < .001). In multivariable analysis, younger age, White race, outpatient setting, and larger nodule size showed significant association with appropriate follow-up completion (P < .015), but structured recommendations did not. Similar results applied for loss to follow-up.DiscussionConsistent use of structured reporting is likely key to mitigate selection bias when benchmarking rates of appropriate follow-up of ILN. Emergency department patients and inpatients are at high risk of missed or delayed follow-up despite structured recommendations. 相似文献
10.